Pfizer Inc (PFE)

[PowerPlay1]

Pfizer to Bolster RSV Vaccination Through Acquisition
April 08 2022 - 09:55AM
TipRanks
Print
Share On Facebook
Pfizer (PFE) has agreed to acquire British antiviral drug developer ReViral for $525 million. PFE stock rose more than 4.3% to close at $55.16 on April 7. The New York-headquartered Pfizer is a multinational pharmaceutical company. Its portfolio includes therapies and vaccines for various diseases, and it is one of the manufacturers of COVID-19 vaccines. Meanwhile, ReViral is developing treatments for respiratory syncytial virus (RSV) and has several drug candidates in the pipeline. Its flagship drug candidate, sisunatovir, is in a Phase 2 study. The experimental drug has been tested in adults with promising results, and now it is being tried in infants.
https://www.tipranks.com/news/pfizer-to-bolster-rsv-vaccination-through-acquisition?utm_source=advfn.com&utm_medium=referral